Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect

Cancer Medicine

Volumn 4, Issue 11, 2015, Pages 1730-1741

  Jia, Yanglei ^a   Ma, Zengyi ^b   Liu, Xiaofei ^a   Zhou, Wenjing ^a   He, Shan ^a   Xu, Xia ^a   Ren, Guijie ^a   Xu, Gang ^b   Tian, Keli ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b 456 Hospital of Chinese PLA   (China)

Author keywords

Colorectal cancer; Diabetes mellitus; Glucose metabolism; Metformin; Warburg effect

Indexed keywords

CYCLINE; DIMETHYLHYDRAZINE; HK PROTEIN; MEMBRANE ENZYME; METFORMIN; PHOSPHOTRANSFERASE; PYRUVATE DEHYDROGENASE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GLYCOLYSIS; IMMUNOHISTOCHEMISTRY; MALE; MEASUREMENT; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BIOMARKERS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METFORMIN; RATS; TUMOR BURDEN;

EID: 84989803081     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.521     Document Type: Article

References (42)

1. Siegel, R., C. DeSantis, and A. Jemal . 2014. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 64:104-117.
2. Berster, J. M., and B. Göke . 2008. Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch. Physiol. Biochem. 114:84-98.
3. Chang, C., and C. Ulrich . 2003. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 46:595-607.
4. Bruce, W. R., A. Giacca, and A. Medline . 2000. Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol. Biomark. Prev. 9:1271-1279.
5. Ko, C., and S. Chaudhry . 2002. The need for a multidisciplinary approach to cancer care. J. Surg. Res. 105:53-57.
6. Deng, L., Z. Gui, L. Zhao, J. Wang, and L. Shen . 2012. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig. Dis. Sci. 57:1576-1585.
7. Jiang, Y., Q. Ben, H. Shen, W. Lu, Y. Zhang, and J. Zhu . 2011. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur. J. Epidemiol. 26:863-876.
8. Jia, Y., G. Xu, W. Zhou, Z. Wang, L. Meng, S. Zhou, etal. 2014. Diabetes promotes DMH-induced colorectal cancer by increasing the activity of glycolytic enzymes in rats. PLoS ONE 9:e110455.
9. Lopaschuk, G. D., R. Wambolt, and R. Barr . 1993. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J. Pharmacol. Exp. Ther. 264:135-144.
10. Weinhouse, S., O. Warburg, D. Burk, and A. L. Schade . 1956. On respiratory impairment in cancer cells. Science 124:267-272.
11. Ye, J., A. Mancuso, X. Tong, P. S. Ward, J. Fan, J. D. Rabinowitz, etal. 2012. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl Acad. Sci. 109:6904-6909.
12. Kirpichnikov, D., S. I. McFarlane, and J. R. Sowers . 2002. Metformin: an update. Ann. Intern. Med. 137:25-33.
13. Collier, C. A., C. R. Bruce, A. C. Smith, G. Lopaschuk, and D. J. Dyck . 2006. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am. J. Physiol. Endocrinol. Metabol. 291:E182-E189.
14. Rena, G., E. R. Pearson, and K. Sakamoto . 2013. Molecular mechanism of action of metformin: old or new insights? Diabetologia 56:1898-1906.
15. Burcelin, R. 2014. The antidiabetic gutsy role of metformin uncovered? Gut 63:706-707.
16. Madiraju, A. K., D. M. Erion, Y. Rahimi, X.-M. Zhang, D. T. Braddock, R. A. Albright, etal. 2014. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542-546.
17. Bowker, S. L., S. R. Majumdar, P. Veugelers, and J. A. Johnson . 2006. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258.
18. Soranna, D., L. Scotti, A. Zambon, C. Bosetti, G. Grassi, A. Catapano, etal. 2012. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17:813-822.
19. Reagan-Shaw, S., M. Nihal, and N. Ahmad . 2008. Dose translation from animal to human studies revisited. FASEB J. 22:659-661.
20. Rodrigues, M., L. Silva, D. Salvadori, J. De Camargo, and M. Montenegro . 2002. Aberrant crypt foci and colon cancer: comparison between a short-and medium-term bioassay for colon carcinogenesis using dimethylhydrazine in Wistar rats. Braz. J. Med. Biol. Res. 35:351-355.
21. Whiteley, L. O., L. Hudson, and T. P. Pretlow . 1996. Aberrant crypt foci in the colonic mucosa of rats treated with a genotoxic and nongenotoxic colon carcinogen. Toxicol. Pathol. 24:681-689.
22. Xu, G., G. Ren, X. Xu, H. Yuan, Z. Wang, L. Kang, etal. 2010. Combination of curcumin and greentea catechins prevents dimethylhydrazine-inducedcolon carcinogenesis. Food Chem. Toxicol. 48:390-395.
23. Srinivasan, K., B. Viswanad, L. Asrat, C. Kaul, and P. Ramarao . 2005. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52:313-320.
24. Srinivasan, K., P. Patole, C. Kaul, and P. Ramarao . 2004. Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find. Exp. Clin. Pharmacol. 26:327-333.
25. Mohania, D., V. K. Kansal, R. Sagwal, and D. Shah . 2013. Anticarcinogenic effect of probiotic Dahi and piroxicam on DMH-induced colorectal carcinogenesis in Wistar rats. Am. J. Cancer Ther. Pharmacol. 1:8-24.
26. Monami, M., C. Lamanna, D. Balzi, N. Marchionni, and E. Mannucci . 2009. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 46:279-284.
27. Bowker, S. L., S. R. Majumdar, P. Veugelers, and J. A. Johnson . 2006. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258.
28. Patel, T., G. Hruby, K. Badani, C. Abate-Shen, and J. M. McKiernan . 2010. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76:1240-1244.
29. Hirsch, H. A., D. Iliopoulos, P. N. Tsichlis, and K. Struhl . 2009. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69:7507-7511.
30. Tanaka, T., H. Kohno, R. Shimada, S. Kagami, F. Yamaguchi, S. Kataoka, etal. 2000. Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats. Carcinogenesis 21:1183-1189.
31. Masakikatyama, N. Y., Y. Yamada, K. Sakata, K. Y. Toshiyakuno, Z. Qiao, P. Q. Vihn, etal. 2002. Preventive effect of fermented brown rice and rice bran against colon carcinogenesis in male F344 rats. Oncol. Rep. 9:817-822.
32. Furukawa, F., A. Nishikawa, Y. Kitahori, Z. Tanakamaru, and M. Hirose . 2002. Spontaneous development of aberrant crypt foci in F344 rats. J. Exp. Clini. Cancer Res. 21:197-201.
33. Bostick, R. M., L. Fosdick, T. J. Lillemoe, P. Overn, J. R. Wood, P. Grambsch, etal. 1997. Methodological findings and considerations in measuring colorectal epithelial cell proliferation in humans. Cancer Epidemiol. Biomark. Prev. 6:931-942.
34. Steinberg, P., A. Klingelhöffer, A. Schäfer, G. Wüst, G. Weisse, F. Oesch, etal. 1999. Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch. 434:213-220.
35. Brinck, U., G. Fischer, E. Eigenbrodt, M. Oehmke, and S. Mazurek . 1994. L-and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch. 424:177-185.
36. Tolle, S. W., R. Dyson, R. Newburgh, and J. M. Cardenas . 1976. Pyruvate kinase isozymes in neurons, glia, neuroblastoma, and glioblastoma. J. Neurochem. 27:1355-1360.
37. Christofk, H. R., M. G. Vander Heiden, M. H. Harris, A. Ramanathan, R. E. Gerszten, R. Wei, etal. 2008. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-233.
38. Mazurek, S., C. B. Boschek, F. Hugo, and E. Eigenbrodt, eds. 2005. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 15:300-308.
39. Hu, X., A.-X. Yu, B.-W. Qi, T. Fu, G. Wu, M. Zhou, etal. 2010. Research the expression and significance of IDH1 and p53 in osteosarcoma. J. Exp. Clini. Cancer Res. 29:43.
40. Robbins, D., J. A. Wittwer, S. Codarin, M. L. Circu, T. Y. Aw, T. T. Huang, etal. 2012. Isocitrate dehydrogenase 1 is downregulated during early skin tumorigenesis which can be inhibited by overexpression of manganese superoxide dismutase. Cancer Sci. 103:1429-1433.
41. Li, W.-L., M.-S. Xiao, D.-F. Zhang, D. Yu, R.-X. Yang, X.-Y. Li, etal. 2014. Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer. Gene 546:263-270.
42. Lv, Q., S. Xing, Z. Li, J. Li, P. Gong, X. Xu, etal. 2012. Altered expression levels of IDH2 are involved in the development of colon cancer. Exper. Therap. Med. 4:801-806.